205 related articles for article (PubMed ID: 30138735)
1. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy.
Bethea ED; Samur S; Kanwal F; Ayer T; Hur C; Roberts MS; Terrault N; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):739-747.e8. PubMed ID: 30138735
[TBL] [Abstract][Full Text] [Related]
2. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.
Chhatwal J; Samur S; Bethea ED; Ayer T; Kanwal F; Hur C; Roberts MS; Terrault N; Chung RT
Hepatology; 2018 Jun; 67(6):2085-2095. PubMed ID: 29222916
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
[TBL] [Abstract][Full Text] [Related]
4. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.
Mazur RD; Goldberg DS
Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients.
Logan C; Yumul I; Cepeda J; Pretorius V; Adler E; Aslam S; Martin NK
Am J Transplant; 2021 Feb; 21(2):657-668. PubMed ID: 32777173
[TBL] [Abstract][Full Text] [Related]
7. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Njei B; McCarty TR; Fortune BE; Lim JK
Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
[TBL] [Abstract][Full Text] [Related]
8. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
10. The Cost-effectiveness of Transplanting Hearts From Hepatitis C-infected Donors Into Uninfected Recipients.
Woolley AE; Gandhi AR; Jones ML; Kim JJ; Mallidi HR; Givertz MM; Baden LR; Mehra MR; Neilan AAM
Transplantation; 2023 Apr; 107(4):961-969. PubMed ID: 36525554
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.
Kadatz M; Klarenbach S; Gill J; Gill JS
Am J Transplant; 2018 Oct; 18(10):2457-2464. PubMed ID: 29797402
[TBL] [Abstract][Full Text] [Related]
12. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
13. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning.
Bethea E; Arvind A; Gustafson J; Andersson K; Pratt D; Bhan I; Thiim M; Corey K; Bloom P; Markmann J; Yeh H; Elias N; Kimura S; Dageforde LA; Cuenca A; Kawai T; Safa K; Williams W; Gilligan H; Sise M; Fishman J; Kotton C; Kim A; Rogers CC; Shao S; Cote M; Irwin L; Myoung P; Chung RT
Am J Transplant; 2020 Jun; 20(6):1619-1628. PubMed ID: 31887236
[TBL] [Abstract][Full Text] [Related]
14. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
[TBL] [Abstract][Full Text] [Related]
15. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis.
Eckman MH; Woodle ES; Thakar CV; Paterno F; Sherman KE
Ann Intern Med; 2018 Aug; 169(4):214-223. PubMed ID: 29987322
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
17. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective.
Saab S; Kardashian A; Saggi S; Choi G; Agopian V; Tong MJ
Clin Transplant; 2018 Oct; 32(10):e13383. PubMed ID: 30129981
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.
Gupta G; Zhang Y; Carroll NV; Sterling RK
Am J Transplant; 2018 Oct; 18(10):2496-2505. PubMed ID: 30075489
[TBL] [Abstract][Full Text] [Related]
19. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
